Abstract Library

#4461 Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): Insights from National Cancer Registration and Analysis Service (NCRAS)

Introduction: ENETS advocates the use of platinum-based chemotherapy in combination with Etoposide as first-line chemotherapy in advanced GEP-NEC. Available retrospective evidence is from small studies.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Paisey S, White B, Chandrakumaran K,

Keywords: Systemic anti-cancer therapy, Chemotherapy, GEP-NEC, NCRAS,

#4407 Characterisation of patients with neuroendocrine tumours in a specialised care institution in oncological endocrinology Bogotá, Colombia

Introduction: Neuroendocrine tumours (NETs) are heterogeneous malignancies that arise from the diffuse neuroendocrine system. Its incidence has increased in the last 3 decades. They have a relatively indolent growth rate and are capable of secreting peptide hormones and biogenic amines.

Conference:

Presenting Author: Florez A

Authors: Rueda M, Florez A, Luna F, Fuentes O, Lizarazo D,

Keywords: Neuroendocrine tumour,

#4352 What can a reference centre offer to patients? Evolution of first visits for neuroendocrine and endocrine tumours and its relation to clinical trials availability.

Introduction: Endocrine and neuroendocrine neoplasia (NEN), which include gastroenteropancreatic neuroendocrine tumours, thyroid cancer and adrenal carcinoma, have a low incidence, making their diagnosis and treatment difficult. Due to this complexity, patients should be managed at specialised centres; however, the lack of official referral networks complicates the concentration of cases.

Conference:

Presenting Author: Martinez-Badal S

Authors: Martínez-Badal S, Hernando Cubero J, García Alvarez A, Elguero B, Alcantara A,

Keywords: Neuroendocrine, Clinical Trial, Reference Centre, Patient referral,

#4294 Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,